Drug Pricing
Drug Pricing
NEW BRIEF: Focus Groups Overwhelmingly Disapprove of Government “Negotiated” Drug Pricing
Today, the Pacific Research Institute published an issue brief revealing overwhelming public disapproval for Medicare reforms that Congress is considering as part of its $3.5 trillion spending bill. Click here to read the full issue brief, “Drug Pricing Proposals Threaten America’s Most Vulnerable Patients.” “It’s a relief that Americans oppose ...
Commentary
Drug Price Controls Inflict Worse Harm Than Even Critics Recognize
It’s no secret that H.R. 3 — the Democrats’ plan to impose price controls on prescription drugs — would have devastating consequences for our healthcare sector. After all, artificially restricting the price of any product invariably leads to shortages, rationing, and a slowdown in both investment and innovation. A new ...
Commentary
Biden’s Prescription Drug Plan Is Nothing More Than Price Controls
The Biden administration’s “Comprehensive Plan for Addressing High Drug Prices,” released last week, paints a vivid picture of the difficulties patients face affording their medicines. “Americans pay too much for prescription drugs,” the report notes. “Many Americans do not take medications as prescribed because of their cost.” How does the administration intend to ...
Commentary
Under Dems’ Drug Pricing Plan, Dozens of New Meds Will Never Be Invented
The Congressional Budget Office just released an analysis of House Democrats’ effort to impose price controls on prescription drugs, H.R. 3 — the Elijah E. Cummings Lower Drug Costs Now Act. The CBO’s chief finding is grim. By drastically limiting pharmaceutical revenue, H.R. 3 would starve scientists of the funding they need ...
Commentary
Budget Reconciliation Bill’s Healthcare Provisions Are Disastrous
Last week, House Democrats passed the $3.5 trillion budget resolution that their Senate counterparts approved earlier this month. The resolution is merely a framework, though. Over the coming months, lawmakers will write the actual legislative text of this mammoth spending bill, which could usher in the most radical changes to our healthcare ...
Drug Pricing
Watch Wayne Winegarden Discuss Drug Pricing Reform with Scripps National News
Watch Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation, discuss his recent study showing how a two-part drug pricing system would ensure prices more accurately reflect how patients value drugs with Scripps National News. The report aired on 60 television stations in 42 markets across the ...
Commentary
The Real Vaccine Skeptics Work at the FDA
Demonstrators in 50 cities across the country took the streets last month to demand a government takeover of America’s health system. The Democrats who control Washington are trying to give those activists what they’re asking for, albeit in piecemeal fashion. In recent weeks, they’ve proposed lowering Medicare’s eligibility age and adding dental, vision and hearing benefits ...
Commentary
Let’s Not Repeat Canada’s Healthcare Mistakes
Demonstrators in 50 cities across the country took the streets last month to demand a government takeover of America’s health system. The Democrats who control Washington are trying to give those activists what they’re asking for, albeit in piecemeal fashion. In recent weeks, they’ve proposed lowering Medicare’s eligibility age and adding dental, vision and hearing benefits ...
Drug Pricing
Watch PRI, Pioneer Institute Webinar on ICER, health care innovation
The Pioneer Institute and Pacific Research Institute hosted an educational webinar on the importance of protecting treatment access, innovation, and equity as Washington addresses drug pricing reforms on July 19, 2021. Pioneer Institute, PRI, and special guests explored the current policy landscape on treatment value and access and how policy ...
Commentary
America’s drug rebate system is broken
Rebates and discounts are generally viewed as important competitive tools that lower prices for consumers, and rightly so. But consumers should beware when discounts create competitive restrictions that reduces their choices and increases their costs. Such is the case when dominant drug manufacturers use rebates to keep lower-priced drugs off ...
NEW BRIEF: Focus Groups Overwhelmingly Disapprove of Government “Negotiated” Drug Pricing
Today, the Pacific Research Institute published an issue brief revealing overwhelming public disapproval for Medicare reforms that Congress is considering as part of its $3.5 trillion spending bill. Click here to read the full issue brief, “Drug Pricing Proposals Threaten America’s Most Vulnerable Patients.” “It’s a relief that Americans oppose ...
Drug Price Controls Inflict Worse Harm Than Even Critics Recognize
It’s no secret that H.R. 3 — the Democrats’ plan to impose price controls on prescription drugs — would have devastating consequences for our healthcare sector. After all, artificially restricting the price of any product invariably leads to shortages, rationing, and a slowdown in both investment and innovation. A new ...
Biden’s Prescription Drug Plan Is Nothing More Than Price Controls
The Biden administration’s “Comprehensive Plan for Addressing High Drug Prices,” released last week, paints a vivid picture of the difficulties patients face affording their medicines. “Americans pay too much for prescription drugs,” the report notes. “Many Americans do not take medications as prescribed because of their cost.” How does the administration intend to ...
Under Dems’ Drug Pricing Plan, Dozens of New Meds Will Never Be Invented
The Congressional Budget Office just released an analysis of House Democrats’ effort to impose price controls on prescription drugs, H.R. 3 — the Elijah E. Cummings Lower Drug Costs Now Act. The CBO’s chief finding is grim. By drastically limiting pharmaceutical revenue, H.R. 3 would starve scientists of the funding they need ...
Budget Reconciliation Bill’s Healthcare Provisions Are Disastrous
Last week, House Democrats passed the $3.5 trillion budget resolution that their Senate counterparts approved earlier this month. The resolution is merely a framework, though. Over the coming months, lawmakers will write the actual legislative text of this mammoth spending bill, which could usher in the most radical changes to our healthcare ...
Watch Wayne Winegarden Discuss Drug Pricing Reform with Scripps National News
Watch Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation, discuss his recent study showing how a two-part drug pricing system would ensure prices more accurately reflect how patients value drugs with Scripps National News. The report aired on 60 television stations in 42 markets across the ...
The Real Vaccine Skeptics Work at the FDA
Demonstrators in 50 cities across the country took the streets last month to demand a government takeover of America’s health system. The Democrats who control Washington are trying to give those activists what they’re asking for, albeit in piecemeal fashion. In recent weeks, they’ve proposed lowering Medicare’s eligibility age and adding dental, vision and hearing benefits ...
Let’s Not Repeat Canada’s Healthcare Mistakes
Demonstrators in 50 cities across the country took the streets last month to demand a government takeover of America’s health system. The Democrats who control Washington are trying to give those activists what they’re asking for, albeit in piecemeal fashion. In recent weeks, they’ve proposed lowering Medicare’s eligibility age and adding dental, vision and hearing benefits ...
Watch PRI, Pioneer Institute Webinar on ICER, health care innovation
The Pioneer Institute and Pacific Research Institute hosted an educational webinar on the importance of protecting treatment access, innovation, and equity as Washington addresses drug pricing reforms on July 19, 2021. Pioneer Institute, PRI, and special guests explored the current policy landscape on treatment value and access and how policy ...
America’s drug rebate system is broken
Rebates and discounts are generally viewed as important competitive tools that lower prices for consumers, and rightly so. But consumers should beware when discounts create competitive restrictions that reduces their choices and increases their costs. Such is the case when dominant drug manufacturers use rebates to keep lower-priced drugs off ...
